Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
West Yorkshire Ileostomy and Internal Pouch Association, Leeds, UK.
Colorectal Dis. 2021 May;23(5):1225-1232. doi: 10.1111/codi.15561. Epub 2021 Feb 21.
Vagus nerve stimulation has emerged as a plausible intervention to reduce ileus after surgery. An early development study was undertaken with the aim of exploring the feasibility of self-administered, noninvasive vagus nerve stimulation (nVNS) after major colorectal surgery.
A parallel-group, randomized controlled trial was undertaken between 1 January 2018 and 31 August 2019. Forty patients undergoing colorectal surgery for malignancy were allocated equally to Sham and Active stimulation groups. Electrical vagus nerve stimulation was self-administered bilaterally over the cervical surface landmarks for 5 days before and after surgery. Outcomes of interest were postoperative complications and adverse events measured using the Clavien-Dindo scale, treatment compliance, device usability according to the Systems Usability Scale (SUS) and clinical measures of bowel recovery.
Forty patients were randomized and one withdrew, leaving 39 for analysis. Postoperative complications occurred in 9/19 (47.4%) participants receiving Sham and 11/20 (55.0%) receiving Active stimulation and were mostly minor. Compliance with treatment before surgery was 4.7 ± 0.9 days out of 5 days in the Sham group and 4.7 ± 1.1 in the Active group. Compliance with treatment after surgery was 4.1 ± 1.1 and 4.4 ± 1.5, respectively. Participants considered the intervention to be 'acceptable' according to the SUS. The most prominent differences in bowel recovery were days to first flatus (2.35 ± 1.32 vs 1.65 ± 0.88) and tolerance of solid diet (2.18 ± 2.21 vs 1.75 ± 0.91) for Sham and Active groups, respectively.
This study supports the safety, treatment compliance and usability of self-administered nVNS in patients undergoing major colorectal surgery.
迷走神经刺激已成为一种合理的干预措施,可减少手术后的肠梗阻。本研究开展了一项早期开发研究,旨在探索自主、无创性迷走神经刺激(nVNS)在结直肠手术后的可行性。
本研究于 2018 年 1 月 1 日至 2019 年 8 月 31 日期间采用平行组、随机对照试验,将 40 例因恶性肿瘤而行结直肠手术的患者等分为 Sham 和 Active 刺激组。在手术前后 5 天内,通过双侧颈表面标志对迷走神经进行电刺激。使用 Clavien-Dindo 量表评估术后并发症和不良事件,使用系统可用性量表(SUS)评估治疗依从性和设备可用性,采用临床方法评估肠道恢复情况。
共 40 例患者被随机分组,其中 1 例退出,39 例患者纳入分析。接受 Sham 治疗的 19 例患者中有 9 例(47.4%)和接受 Active 治疗的 20 例患者中有 11 例(55.0%)发生术后并发症,且均为轻微并发症。在 Sham 组,术前治疗的依从性为 5 天中的 4.7±0.9 天,在 Active 组为 4.7±1.1 天。术后治疗的依从性分别为 4.1±1.1 天和 4.4±1.5 天。根据 SUS,参与者认为干预措施“可接受”。在肠道恢复方面,最显著的差异是首次排气的天数(Sham 组为 2.35±1.32 天,Active 组为 1.65±0.88 天)和固体饮食的耐受天数(Sham 组为 2.18±2.21 天,Active 组为 1.75±0.91 天)。
本研究支持自主、无创性 nVNS 在结直肠大手术患者中的安全性、治疗依从性和可用性。